Neurophet

Neurophet operates at the intersection of medical imaging software, neuroscience, and neuromodulation. Its product scope spans neurodegenerative disease assessment through Neurophet AQUA and AQUA AD Plus, multiple-sclerosis imaging through AQUA MS, and personalized transcranial electrical-stimulation planning through tES LAB. This creates a broader offering than a single-purpose diagnostic application: the company combines imaging interpretation, treatment-decision support, and therapeutic planning. The strongest visible differentiator is the integration of AI analysis with disease-specific clinical workflows, including Alzheimer’s treatment eligibility, side-effect monitoring, and outcome evaluation. Regulatory progress strengthens its market access, with FDA 510(k) clearance for AQUA AD Plus and two additional U.S. regulatory milestones referenced in company announcements. Its 2026 collaborations with VHIR and ALZ-NET also connect the platform to algorithm validation and therapy-monitoring infrastructure. The available comparable-company records do not identify distinct external competitors; they repeat Neurophet itself, so relative market-share claims cannot be substantiated. Competitive pressure is likely to come from established medical-imaging software vendors, neurology-focused AI developers, and device companies, but public information here is insufficient to rank Neurophet against named peers.

Neurophet’s trajectory shows a shift from early-stage Korean neurotechnology development toward public-company financing and international commercialization. Founded on Mar 14, 2016, the company completed early assistance and pre-seed activity before raising two Series A tranches in 2019 and 2020, followed by a $16.1 million Series B in 2021 and a $15.3 million Series C in 2023. It entered the public market on Jul 25, 2025 at an indicated valuation of approximately $116.2 million and raised $10.8 million each through post-IPO equity and post-IPO debt on Apr 10, 2026. Product development has increasingly focused on neurodegenerative disease workflows: AQUA AD was introduced in 2025, AQUA AD Plus received FDA clearance on Feb 6, 2026, and AQUA MS entered joint validation with VHIR on May 26, 2026. Commercial supply agreements with Raffles Medical and Elevate Clinic in July and August 2026 provide evidence of international deployment rather than only research positioning. Leadership expansion also supports this phase, including Josh Cohen’s Americas appointment on Dec 2, 2025 and the addition of scientific advisors.